SCHEMBL6099731

SCHEMBL6099731

O=C(O)C1(S(=O)(=O)N2CCC(Oc3ccc(C(F)(F)F)cc3)CC2)CCSCC1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 7/20 0.49
MMP2 P08253 6/20 0.49
MMP12 P39900 1/20 0.46
FPR2 P25090 1/20 0.46
PROKR1 Q8TCW9 1/20 0.46
EPHX2 P34913 3/20 0.44
LIPE Q05469 1/20 0.44
TEAD1 P28347 1/20 0.43
ADRB2 P07550 1/20 0.41
LIPG Q9Y5X9 2/20 0.40
LIPC P11150 1/20 0.40
TP53 P04637 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MMP3 P08254 1/20 0.39
MMP9 P14780 1/20 0.39
MMP8 P22894 1/20 0.39
MMP14 P50281 1/20 0.39
EPHX1 P07099 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6094760 0.90 MMP13 (0.49) MMP13MMP2MMP12FPR2PROKR1
SCHEMBL6095742 0.89 MMP13 (0.54) MMP13MMP2MMP12FPR2PROKR1
SCHEMBL6097841 0.88 MMP13 (0.49) MMP13MMP2MMP12FPR2PROKR1
SCHEMBL6096620 0.82 ADRB2 (0.52) MMP13MMP2MMP12EPHX2LIPE
SCHEMBL6095160 0.82 MMP13 (0.47) MMP13MMP2MMP12FPR2PROKR1
SCHEMBL6097338 0.82 MMP13 (0.47) MMP13MMP2MMP12FPR2PROKR1
SCHEMBL6096034 0.81 MMP13 (0.42) MMP13MMP2MMP12FPR2PROKR1
SCHEMBL6095614 0.79 ACACB (0.47) MMP13MMP2MMP12FPR2PROKR1
SCHEMBL6097048 0.79 MMP13 (0.54) MMP13MMP2MMP12FPR2PROKR1
SCHEMBL6098501 0.78 GPR119 (0.44) MMP13MMP2MMP12FPR2PROKR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067670-B2 Sulfamato hydroxamic acid metalloprotease inhibitor WARNER LAMBERT COMPANY (US) 2006-06-27 US disclosed
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2005-03-03 US disclosed
US-6800646-B1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2004-10-05 US disclosed
US-6492367-B1 Sulfamato hydroxamic acid metalloprotease inhibitor G. D. SEARLE & COMPANY 2002-12-10 US disclosed
US-6448250-B1 INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 G. D. SEARLE & COMPANY 2002-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor MMP14, MMP12, MMP17 MMP13 23/4885MMP2 8/4885MMP12 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.